27.75
Summit Therapeutics Inc stock is traded at $27.75, with a volume of 2.18M.
It is down -0.53% in the last 24 hours and up +59.87% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$27.90
Open:
$27.9
24h Volume:
2.18M
Relative Volume:
0.58
Market Cap:
$17.91B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-86.71
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
+15.11%
1M Performance:
+59.87%
6M Performance:
+36.11%
1Y Performance:
+532.18%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SMMT
Summit Therapeutics Inc
|
27.73 | 17.91B | 956.00K | -221.32M | -142.25M | -0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.09 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
604.05 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
655.78 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.27 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.39 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
Mar-12-25 | Initiated | Evercore ISI | Outperform |
Feb-28-25 | Initiated | Goldman | Buy |
Jan-08-25 | Initiated | Truist | Buy |
Dec-11-24 | Initiated | Wells Fargo | Overweight |
Dec-06-24 | Initiated | Jefferies | Buy |
Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
Aug-12-24 | Initiated | H.C. Wainwright | Buy |
May-07-24 | Initiated | Citigroup | Buy |
Mar-26-24 | Initiated | Stifel | Buy |
Jun-28-18 | Downgrade | Janney | Buy → Neutral |
May-02-18 | Initiated | Janney | Buy |
Apr-12-18 | Reiterated | Needham | Buy |
Feb-13-18 | Initiated | BTIG Research | Buy |
Jan-04-18 | Initiated | SunTrust | Buy |
Dec-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
Oct-05-16 | Reiterated | Needham | Buy |
Sep-16-16 | Initiated | H.C. Wainwright | Buy |
Mar-30-15 | Initiated | Needham | Buy |
Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
These 10 Firms Soared Last Week, Here’s Why - Insider Monkey
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey
This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail
Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus
Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus
Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus
Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus
Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus
Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa
Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com
Summit Therapeutics stock holds $44 target despite drop - Investing.com
Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India
Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada
Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com
Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus
Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı
BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı
Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus
Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus
Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize
Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks
Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus
Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade
Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):